PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

PTC Therapeutics, Inc.

PTC Therapeutics is a global biopharmaceutical company that delivers transformative therapies for people living with rare diseases, focusing on creating new therapies that address the underlying causes of diseases.

msh id	COM:PTCBIO
symbol	PTCT
name	PTC Therapeutics, Inc.
homepage url	https://www.ptcbio.com
country	US
sector	Healthcare
industry	Biotechnology
market	STOCKS
employee count	988
crunchbase url	-
linkedin url	-
founders	-

market cap	2.44B
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.13
growth cost of revenue	5.45
growth depreciation and amortization	2.51
growth ebitda	0.7
growth ebitda ratio	0.77
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-0.01
growth gross profit ratio	-0.26

COM:PTCBIO

PTC Therapeutics

Last Close

41.96

21/11 21:00

Market Cap

2.44B

Beta: -

Volume Today

581.57K

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	1.29B
cost of revenue	1.29B
depreciation and amortization	236.59M
ebitda	-112.81M
ebitda ratio	-0.12
eps	-8.37
eps diluted	-8.37
operating expenses	999.1M
operating income	-349.4M
operating income ratio	-0.37

accounts receivables	-1.54M
capital expenditure	-120.62M
cash at beginning of period	279.83M
cash at end of period	594M
inventory	30.58M
working capital ttm	48.24M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-